Cargando…
Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin
Development of innovative more effective therapy is required for refractory osteosarcoma patients. We previously established that glycogen synthase kinase-3β (GSK- 3β) is a therapeutic target in various cancer types. In the present study, we explored the therapeutic efficacy of GSK-3β inhibition aga...
Autores principales: | Shimozaki, Shingo, Yamamoto, Norio, Domoto, Takahiro, Nishida, Hideji, Hayashi, Katsuhiro, Kimura, Hiroaki, Takeuchi, Akihiko, Miwa, Shinji, Igarashi, Kentaro, Kato, Takashi, Aoki, Yu, Higuchi, Takashi, Hirose, Mayumi, Hoffman, Robert M, Minamoto, Toshinari, Tsuchiya, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363568/ https://www.ncbi.nlm.nih.gov/pubmed/27780915 http://dx.doi.org/10.18632/oncotarget.12781 |
Ejemplares similares
-
Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma
por: Abe, Kensaku, et al.
Publicado: (2019) -
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment
por: Domoto, Takahiro, et al.
Publicado: (2020) -
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study
por: Kimura, Hiroaki, et al.
Publicado: (2015) -
Glycogen synthase kinase‐3β participates in acquired resistance to gemcitabine in pancreatic cancer
por: Uehara, Masahiro, et al.
Publicado: (2020) -
Treatment of infected calcific myonecrosis with chronically discharging sinus caused by iatrogenic aspiration: A case report
por: Higuchi, Takashi, et al.
Publicado: (2022)